HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of the low-molecular-weight heparin nadroparin during pregnancy. A review.

Abstract
Antithrombotic therapy is often used during pregnancy for the treatment and prevention of venous thromboembolism, the prevention of systemic embolism in patients with heart valve prostheses and the prevention of foetal loss in patients with antiphospholipid syndrome. Low-molecular-weight heparins (LMWHs), including nadroparin, have largely replaced unfractionated heparin as the anticoagulant of choice. The use of the LMWH nadroparin in pregnant women at an increased risk of thromboembolism or foetal loss is discussed in this review. Deep vein thrombosis can be effectively treated or prevented with nadroparin without any serious adverse events. Nadroparin 0.1 ml/10 kg s.c. once daily prevents thromboembolic complications in pregnant women with heart valve prostheses. Nadroparin is also effective in preventing foetal loss, through contributing to normal placental development and in decreasing the risk of premature delivery in pregnant women with antiphospholipid syndrome or women with herpes and antiphospholipid syndrome. These results demonstrate nadroparin is effective, easy to administer and associated with a low incidence of foetal and maternal complications. The use of nadroparin at a prophylactic dose of 0.3 ml (2850 IU AXa, 95 IU/kg) (for high-risk patients, 0.3-0.6 ml) s.c. once daily, and a therapeutic dose of 0.1 ml/10 kg (95 IU/kg) s.c. twice daily, is in line with the latest international guidelines of the American College of Chest Physicans.
AuthorsAlexander D Makatsaria, Victoria O Bitsadze, N V Dolgushina
JournalCurrent medical research and opinion (Curr Med Res Opin) Vol. 19 Issue 1 Pg. 4-12 ( 2003) ISSN: 0300-7995 [Print] England
PMID12661774 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Fibrinolytic Agents
  • Nadroparin
Topics
  • Antiphospholipid Syndrome (complications)
  • Female
  • Fibrinolytic Agents (therapeutic use)
  • Heart Valve Prosthesis
  • Herpes Simplex (complications)
  • Humans
  • Nadroparin (therapeutic use)
  • Pregnancy
  • Pregnancy Complications, Hematologic (drug therapy, prevention & control)
  • Pregnancy Complications, Infectious (virology)
  • Russia
  • Venous Thrombosis (complications, drug therapy, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: